HALEON

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Sep 4, 2026TrialAn 8-Week, Randomised, Controlled, Double-Blind, Clinical Study to Assess the Efficacy of a Calcium Sodium Phosphosilicate Toothpaste for the Relief of Dentine Hypersensitivity

Aug 26, 2026TrialClinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice

Aug 18, 2026TrialStudy to Investigate the Effect of Changes in Dentinal Hypersensitivity on Oral Health Parameters

Aug 13, 2026TrialAn 8-Week Randomized, Controlled, Examiner-Blind, Clinical Study Investigating the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival Health

Aug 6, 2026TrialA 24-Week, Randomised, Controlled, Examiner-blind, Clinical Study to Evaluate the Efficacy of an Experimental Stannous Fluoride Dentifrice in Improving Gingival Health and Reducing Plaque Accumulation

Aug 4, 2026TrialA Proof of Concept Study to Evaluate the Efficacy of Two Experimental Mouthwash Formulations in the Relief of Dentinal Hypersensitivity

Jul 22, 2026TrialA Real-World Evidence Study Evaluating Oral Health Related Quality of Life With Use of a Calcium Sodium Phosphosilicate Anti-Sensitivity Dentifrice for Dentin Hypersensitivity Management

Jul 2, 2026TrialA Phase I, Randomised, Open Label, Single Center, Single Oral Dose, Three Treatment, Three Period, Three Sequence, Change-over Bioequivalence Study of Paracetamol Orodispersible Tablet 500 mg (Haleon) to Assess Bioequivalence With Alvedon 500 mg Film-Coated Tablet (Haleon, Sweden) and Panadol 500 mg Film-Coated Tablet (Haleon, Australia) in Healthy Adult Subjects Under Fasting Conditions

2 more events

Jul 1, 2026TrialA Phase I, Single-Center, Open-Label, Single-Dose, Pharmacokinetic Study to Evaluate Ibuprofen (IBU) 62.5 mg and Acetaminophen (APAP) 125 mg/5 ml in an Oral Liquid Suspension Fixed-Dose Combination Product in Children Aged 6 to 11 Years

Jan 16, 2026TrialA Clinical Study to Evaluate the Effectiveness of an Test Toothpaste for the Relief of Dentin Hypersensitivity in a Chinese Population

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

NicoretteApr 30, 2028 Nicorette2 patentsApr 30, 2029

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Tavist — TAVIST

Application NDA017661 (NDA)

19851 event

FDAJun 28

Tavist — TAVIST

Application NDA018675 (NDA)

19881 event

FDAApr 12

Axid — AXID

Application NDA019508 (NDA)

19921 event

FDAAug 21

Tavist — TAVIST-1

Application NDA020925 (NDA)

19965 events

FDAMay 9

Axid — AXID AR

Application NDA020555 (NDA)

FDAFeb 9

Nicorette — NICORETTE

Application NDA020066 (NDA)

FDAFeb 9

Nicorette — NICORETTE

Application NDA018612 (NDA)

FDAFeb 9

Nicorette — NICORETTE

Application NDA018612 (NDA)

FDAFeb 9

Nicorette — NICORETTE

Application NDA020066 (NDA)

20001 event

FDAJul 25

Abreva — ABREVA

Application NDA020941 (NDA)

20022 events

FDAOct 31

Nicorette — NICORETTE

Application NDA021330 (NDA)

FDAOct 31

Nicorette — NICORETTE

Application NDA021330 (NDA)

20041 event

FDAMay 25

Axid — AXID

Application NDA021494 (NDA)

20092 events

FDAMay 18

Nicorette — NICORETTE

Application NDA022360 (NDA)

FDAMay 18

Nicorette — NICORETTE

Application NDA022360 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)